Question · asked by 1 review
Mirtazapine adjunct vs placebo adjunct: Leaving the study early
- Population
- schizophrenia
- Intervention
- Mirtazapine adjunct
- Comparison
- placebo adjunct
- Outcome
- Leaving the study early
Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Mirtazapine adjunct vs placebo adjunct Leaving the study early for any reason · schizophrenia Mirtazapine adjunct showed no clear difference in leaving the study early for any reason compared with placebo adjunct (moderate certainty). Mirtazapine adjunct for people with schizophrenia (2018) · Cochrane Headline outcomes only | RR 1.03 [0.64, 1.66] | 9 studies · 310 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mirtazapine adjunct for people with schizophrenia 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.